Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

20-01-2021 | Urothelial cancer | Video

Key results on urothelial carcinoma presented at ASCO GU 2021

Speakers: Frederik Liedberg and Thomas Powles

Fredrik Liedberg and Thomas Powles discuss their thoughts on the game-changing results on metastatic urothelial carcinoma presented at ASCO GU. They cover updates on EV-301, JAVELIN Bladder 100, and their preferences on treatment sequencing. Also, they talk about the importance of CheckMate 274 in nonmetastatic patients, and discuss potential future approaches in this setting (15:35).

This activity is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits